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Abstract
Most pediatric asthma guidelines offer evidence-based or best practice approaches to the management of asthma exacerbations
but struggle with evidence-based approaches for severe acute asthma (SAA).We aimed to investigate current practices in children
with SAA admitted to European pediatric intensive care units (PICUs), in particular, adjunct therapies, use of an asthma severity
score, and availability of a SAA guideline.We designed a cross-sectional electronic survey across European PICUs. Thirty-seven
PICUs from 11 European countries responded. In 8 PICUs (22%), a guideline for SAA management was unavailable. Inhaled
beta-agonists and anticholinergics, combined with systemic steroids and IVMgSO4 was central in SAA treatment. Seven PICUs
(30%) used a loading dose of a short-acting beta-agonist. Eighteen PICUs (49%) used an asthma severity score, with 8 different
scores applied. Seventeen PICUs (46%) observed an increasing trend in SAA admissions.
Conclusion: Variations in the treatment of children with SAA mainly existed in the use of adjunct therapies and asthma
severity scores. Importantly, in 22% of the PICUs, a SAA guideline was unavailable. Standardizing SAA guidelines across
PICUs in Europe may improve quality of care. However, the limited number of PICUs represented and the data compilation
method are constraining our findings.
What is Known:
• Recent reports demonstrate increasing numbers of children with SAA requiring PICU admission in several countries across the world.
•Most pediatric guidelines offer evidence-based approaches to the management of asthma exacerbations, but struggle with evidence-based approaches
for SAA beyond these initial steps.
What is New:
• A large arsenal of adjunct therapies and 8 different asthma scores were used.
• In a large number of PICUs, a written guideline for SAA management is lacking.
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Abbreviations
BTS British Thoracic Society
ECMO Extracorporeal membrane oxygenation
ED Emergency department
ESPNIC European Society of Paediatric
and Neonatal Intensive Care
HFNC High-flow nasal cannula
IV Intravenous
MgSO4 Magnesium sulfate
PICU Pediatric intensive care unit
PK Pharmacokinetics
PTSD Posttraumatic stress disorder
NIV Non-invasive mechanical ventilation
RAD Respiratory rate, accessory muscle use,
decreased breath sounds score
RCT Randomized controlled trial
SAA Severe acute asthma
SABA Short-acting beta-agonist
SCAMP Standardized clinical assessment and
management plan
SIGN Scottish Intercollegiate Guidelines Network
Introduction
Severe acute asthma (SAA), also known as status asthmaticus,
is a severe or life-threatening asthma exacerbation, which does
not respond to conventional treatment with inhaled short-
acting beta-agonist (SABA) and systemic corticosteroids [1].
SAA has the potential to progress to respiratory failure and
can be fatal [2]. SAA requiring admission to the pediatric
intensive care unit (PICU) occurs in approximately 5–16%
of all asthma hospitalizations [3–5]. Recent reports demon-
strate increasing numbers of children requiring PICU admis-
sion in several countries across the continents [3, 5–7].
Most pediatric asthma guidelines offer evidence-based ap-
proaches to the management of asthma exacerbations (oxy-
gen, inhaled beta-agonists, and systemic corticosteroids).
However, they struggle with an evidence-based approach for
SAA beyond these initial steps [8–10]. There is a broad arse-
nal of adjunct therapies in case the child is not responding to
conventional treatment, but the evidence is often unclear, con-
flicting or absent in the context of PICU care in literature.
Adjunct therapies that are often suggested in children with
SAA are intravenous (IV) magnesium sulfate (MgSO4), IV
theophylline, and IV salbutamol.
A recent meta-analysis suggested that IV MgSO4 is likely
to be effective in avoiding hospitalization and improving air-
way patency in children with asthma exacerbation [11].
MgSO4 has the advantage of widespread availability, low
cost, and minimal adverse effects. Another advantage of
MgSO4 is the potential ability to block beta 1-adrenergic
effects of salbutamol, which can prevent tachycardia due to
IV salbutamol [12].
Methylxanthines (e.g., theophylline) are another option in the
setting of SAAmanagement, although not recommended in USA
guidelines [13]. The British Thoracic Society (BTS) and the
Scottish IntercollegiateGuidelinesNetwork (SIGN) guideline state
that aminophylline can be considered for children unresponsive to
maximal doses of bronchodilators and steroids [14].
Severe bronchial constriction can prevent the delivery of
inhaled beta-agonists to the distal airways in children with
SAA; IV beta-agonists may cause more effective
bronchodilation [9]. A single dose of IV salbutamol might be
effective on time to discharge from hospital or PICU, duration
of nebulization of salbutamol, and clinical asthma scores. But
the evidence for a beneficial effect of a loading dose of IV
salbutamol is lacking. There are several available pediatric asth-
ma scores, but none of them has been sufficiently validated for
children with SAA, especially in the PICU setting [15].
We aimed to characterize the current practices of children
with SAA in European PICUs, in particular, adjunct therapies,
use of an asthma severity score as a tool for evaluating the
effectiveness of interventions, and use of a guideline for SAA
management. We hypothesized that SAA management, espe-
cially beyond the initial treatment steps, varied widely be-
tween European PICUs. SAA exacerbations are associated
with significant morbidity and can be fatal. In view of the
life-threatening aspect of SAA and recent reports of increasing
SAA PICUs admissions worldwide, this calls for a strict SAA
management, to improve patient care and reduce PICU admis-
sions. Furthermore, with this survey, we could identify future
research questions and priorities across Europe, with the ulti-
mate aim to optimize and standardize SAA management in
European PICUs.
Materials and methods
We conducted a cross-sectional electronic survey (using
LimeSurvey, supplemental data 1) across all European
Society of Paediatric and Neonatal Intensive Care (ESPNIC)
members in 54 European countries (exact number of PICUs
unknown). The survey was designed by the authors and
instrumentalized in order to address all aspects of the research
question and hypothesis. Questions were based on current
published guidelines and themes emerging from recent litera-
ture on PICU treatment of life-threatening asthma in the
PICU. The questions in our survey were clear and straightfor-
ward, with an appropriate length of the questionnaire and
check questions. The survey was piloted on three PICU phy-
sicians for clarity and face validity. The questionnaire was
written in English; it included 43 questions divided into 4
sections (general information, SAA in the PICU, medication,
and follow-up) requiring 15 min on average to complete.
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Pediatric physicians working at a PICU in Europe were invit-
ed through the ESPNIC newsletter and by email to complete
the questionnaire online [16]. We asked only one clinician to
respond per PICU for feasibility reasons.
The survey was undertaken between November 2017 and
April 2018. The database contains information regarding PICU
characteristics, admission criteria, respiratory support, treat-
ment, trend in SAA PICU admissions, and mortality. For fea-
sibility reasons, we did not ask for the exact numbers of mor-
tality and PICU admissions for children with SAA, but only a
range in percentages. Each completed survey was entered into a
password-protected database for analysis. Data were collected
electronically in a case report form. Responses to the question-
naire were anonymous but site coded.
Data were descriptively analyzed. For regional differences,
countries were divided into 3 geographical areas: Northern
Europe (the Netherlands, Finland, and UK), Central Europe
(France, Germany, and Belgium), and Southern Europe (Spain,
Portugal, Turkey, Greece, and Italy), as described in previous
studies [17]. Differences between regions and type of hospital
were tested using the chi-square test. To assess differences in
treatment by number of PICU beds available, the linear-by-
linear chi-square association was used. All statistical analyses
were carried out in SPSS version 21 (Chicago, IL, USA).
Results
Thirty-eight physicians from 37 PICUs located in 11
European countries responded to the survey (Table 1). Of 1
PICU, 2 physicians responded to the survey, these responses
were combined. The characteristics of the PICUs are de-
scribed in appendix (Table 2). Severity of the SAA, the type
of respiratory support, and the type ofmedication neededwere
the main primary indications for PICU admission (Table 3).
The usual treatment for children with SAA was inhaled
salbutamol combined with systemic steroids, an anticholiner-
gic and IVMgSO4 (Table 4). Seven of 23 PICUs (30%) used a
SABA IV loading dose. Different adjunct therapies were used
in the PICUs (Fig. 1). The stepwise approach to the treatment
of children with SAA differed significantly between all
PICUs, with 25 different therapeutic options (supplemental
Table 1). To assess the SAA severity, an asthma severity score
was used in 18 PICUs (49%), with 8 different asthma scores
used. The asthma score [18] was used most frequently (n = 7),
followed by the respiratory rate, accessory muscle use, and
decreased breath sounds score (RAD) (n = 4) [19].
Auscultation and accessory muscle use were represented in
all asthma scores.
Table 1 Respondent characteristics
Respondents Number of sites (%) a
Country
The Netherlands 7 (19)
France 6 (16)
Spain 6 (16)
Germany 5 (14)
UK 3 (8)
Portugal 3 (8)
Belgium 2 (5)
Turkey 2 (5)
Finland 1 (3)
Greece 1 (3)
Italy 1 (3)
Specialty
Pediatric intensivist 35 (95)
Pediatric anesthesiologist 2 (5)
PICU experience (years)
1–5 3 (8)
6–10 5 (14)
11–20 17 (46)
> 20 12 (32)
a 38 respondents of 37 PICUs, 2 sites were combined
Table 2 PICU characteristics
PICU characteristics Number (%, N = 37)
Hospital
General hospital 1 (3)
University hospital 20 (54)
Children’s hospital 6 (16)
University children’s hospital 10 (27)
PICU beds
1–10 14 (38)
11–20 19 (51)
21–30 3 (8)
> 30 1 (3)
PICU combined with ICU/NICU 10 (27)
Cardiac surgery 13 (35)
Overall PICU admissions per year
< 250 1 (3)
251–500 17 (46)
501–750 8 (22)
751–1000 6 (16)
1001–1500 4 (11)
> 1500 1 (3)
Overall PICU mortality per year
0–3% 16 (43)
4–5% 15 (41)
6–10% 6 (16)
Overall proportion IMV a per year
< 25% 7 (19)
25–50% 16 (43)
50–75% 10 (27)
> 75% 4 (11)
a Invasive mechanical ventilation
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Twenty-nine PICUs (78%) used a written guideline to treat
children with SAA in their hospital. Of these PICUs, 18 used a
local guideline, 10 a national guideline (UK [14], the
Netherlands [20], France (guideline not specified)), and 1 an
international guideline (Greece [2]).
The use of invasive mechanical ventilation (IMV) differed
widely between PICUs, from none up to 31–50% of all chil-
dren with SAA being mechanically ventilated. Non-invasive
mechanical ventilation (NIV) and high-flow nasal cannula
(HFNC) was used > 50% of SAA cases in 10 and 12
PICUs, respectively (Table 5). Mortality due to SAAwas 0–
3% in 36 PICUs (4–5% in 1 PICU). The number of SAA
PICU admissions per center ranged from 12 to 250 the last 5
years, with a median of 50 (IQR 20–100). Seventeen physi-
cians (46%) reported an increasing trend in children with SAA
admitted to the PICU (based on local database n = 9, personal
impression n = 8). We did not ask for the exact numbers of
PICU admissions for feasibility reasons. In 24 PICUs (65%), a
follow-up visit was scheduled, mostly with a pediatric pulmo-
nologist, within 6 weeks after PICU discharge.
Asthma management by region, type of hospital, and num-
ber of PICU beds available is shown in Table 6. In the
Southern European countries, an asthma severity score was
used significantly more compared with Central and Northern
European countries (p = 0.032).
Discussion
This survey showed that most European PICUs were adherent
to proven initial treatment for children with SAA. However,
intensification with the use of adjunct therapies varied widely.
A large arsenal of adjunct therapies was used despite even less
evidence of efficacy. Gathering evidence for these strategies
warrants further studies as a first step towards evidence-based
clinical guidelines for SAA in children. Ketamine and antibi-
otics were frequently used in children with SAA across
European PICUs. However, both ketamine and antibiotics
have no effect on hospital admission rate, or need for mechan-
ical ventilation [21, 22].
A loading dose of IV salbutamol can lead to relatively higher
salbutamol levels immediately after infusion with a possible
therapeutic advantage. Few small studies reported an effect on
time to discharge from hospital or PICU, duration of nebuliza-
tion of salbutamol, and clinical asthma scores after a bolus of IV
salbutamol [23, 24] or terbutaline [25], [26, 27]. In some
PICUs, methylxanthines were standard treatment for children
with SAA, although again a Cochrane review in 2005 showed
no reduction in symptoms, number of nebulized treatment, and
length of hospital stay [28]. Evidence regarding mucolytic
drugs and epinephrine for children with SAA is limited. Nitric
oxide, heliox, sodium bicarbonate, and inhaled anesthetics are
rarely used in the treatment of children with SAA.
There are several available pediatric asthma scores, but
none of them has been sufficiently validated for children with
SAA [15]. It is essential to adapt and validate an existing
dyspnea score, specific for the intensive care setting. A
Table 4 Medication used in the treatment of SAA at the PICU
Medication N of PICU (%, N = 37)
Inhalation with salbutamol 37 (100)
Systemic corticosteroid a 37 (100)
IV 16 (43)
Oral or IV 21 (57)
Inhalation with an anticholinergic 35 (95)
IV MgSO4
b 35 (95)
25 mg/kg 8 (23)
40 mg/kg 12 (34)
50 mg/kg 10 (29)
> 50 mg/kg 2 (6)
SABA IV loading dose c 7 (19)
Salbutamol 5 (71)
Reproterol d 2 (29)
< 10 mcg/kg 4 (57)
10–15 mcg/kg 3 (43)
a Route of administration of the systemic corticosteroids
b Dose of MgSO4
c Type of SABA
dDose of reproterol
Table 3 Primary indications for PICU admission in children with SAA
Admission criteria N of PICU (N = 37)
Clinical signs a 35
Persisting respiratory distress 28
Apparent fatigue 28
Altered level of consciousness 30
Respiratory support a 37
NIV b 34
HFNC c 16
Invasive mechanical ventilation 33
Medication a 25
Continuous nebulization 9
MgSO4 IV 1
SABA IV loading dose 6
SABA IV continuous infusion 23
* Independent of dose 22
* Dependent of dose 1
a At least one of these, multiple criteria were possible
b Non-invasive mechanical ventilation
c High-flow nasal cannula
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validated asthma score is needed to study the efficacy of dif-
ferent interventions in the context of PICU care.
A striking observation is that 22% of the PICUs did not
have written guidelines for the management of children with
SAA. Asthma treatment protocols in the ED were effective in
improving some areas of management, including drug therapy
[29, 30]. However, the lack of evidence for many of the
above-mentioned treatments hampers the development of an
evidence-based guideline. In the vast majority of PICU prac-
tices, strong supportive evidence is lacking before a therapy is
applied. However, proving the treatment’s effectiveness after
implementing the therapy in practice is important. Overall,
each PICU cares for a small number of heterogeneous patients
with relatively rare diseases, which emphasizes the need for
international collaboration. An integral approach to improve
care could be realized through a standardized clinical assess-
ment and management plan (SCAMP) and might provide ev-
idence of the effectiveness of these therapies [8].
In most European PICUs clinical assessment, type of respi-
ratory support and SABA IV continuous infusion were the
main PICU admission criteria. HFNC as a PICU admission
criterion is reported in half of the responding PICUs. HFNC is
frequently used in children with SAA, which is in line with a
previous study, where a significant increase in the use of
HFNC since 2010 is reported [6]. Only 1 observational study
evaluated the use of HFNC in children with SAA [31].
Mortality due to SAAwas low, and the use of IMV was rare.
Unfortunately, no association can be made between lack of
written guidelines and mortality, or proportion of IMV, be-
cause these variables were reported in a range.
For one-third of the patients, no follow-up visit was sched-
uled for the child after PICU discharge. These children are at
risk for more severe asthma exacerbations with PICU read-
mission [3] and undertreatment with inhaled corticosteroids.
A long-term follow-up with targeted management seems a
crucial preventive measure and warranted to prevent
readmissions for SAA.
Limitations
This survey was carefully designed and instrumentalized in
order to address all aspects of the research question and hy-
pothesis. However, it is possible that not all relevant themes
have been addressed.
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Fig. 1 Adjunct therapies
Table 5 Respiratory support in children with SAA
Respiratory support N of PICU (%, N = 37)
NIV a or CPAP b
< 25% 17 (46)
25–50% 10 (27)
51–75% 5 (14)
> 75% 5 (14)
HFNC c
< 25% 21 (57)
25–50% 4 (11)
51–75% 7 (19)
> 75% 5 (14)
Invasive mechanical ventilation
Never 4 (11)
1–10% 24 (65)
11–30% 7 (19)
31–50% 2 (5)
a Non-invasive ventilation
b Continuous positive airway pressure
c High-flow nasal cannula
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This survey might not be representative for all PICUs in
Europe, since only 11 of the 54 ESPNIC countries participated
and Eastern and Northern Europe were underrepresented.
ESPNIC has more than 600 members from 54 countries, but
the relation of members to the exact number of European
PICUs who received the invitation for the survey cannot be
determined. So, despite the existence of a European Society ded-
icated to pediatric intensive care and its professionals (ESPNIC),
performing a survey among ESPNIC members turned out to be
highly challenging.Although a survey amongESPNICmembers
is a practical approach, it might not capture the full range of
European PICU practice. Finally, we must recognize although
an ESPNIC SAA guideline is needed, adherence could also be
challenging. Another limitation of this study, as with any survey,
is a bias of self-reporting, which provides no validation of the
accuracy of the data provided. We asked only one clinician to
respond per PICU for feasibility reasons. This may have led to
subjective information not representing local PICU policy.
Conclusion
Inhaledbeta-agonists andanticholinergics combinedwith systemic
steroids and IV MgSO4 were central in the SAA treatment.
Importantly, in22%ofthePICUs,writtenguidelineswerenotavail-
able. However, the limited number of PICUs represented and the
data compilationmethod,with bias, are constraining our findings.
Future research questions should focus on the use of adjunct
therapies in life-threatening SAA. In our opinion, the role of IV
salbutamol including a loading dose should be determined. Also,
the place of high-flowoxygen aswell asNIVneeds further study.
Furthermore, validating an asthma severity score for use in a
PICU setting as a tool for evaluating the effectiveness of inter-
ventions is essential. The ultimate aim is to establish an ESPNIC
SAA guideline based on evidence and implementation of the
guideline in European PICUs. Standard of care within
European PICUs provides useful data which can lead to relevant
research questions in future. Finally, priority should be to reduce
the number of children with SAA requiring PICU admission by
identifying risk factors for PICU admissions, better treatment at
the ED and pediatric ward (e.g., loading dose IV salbutamol),
and strict PICU admission criteria (e.g., continuous infusion of
IV salbutamol > 1–2 mcg/kg/min, NIV).
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Table 6 SAA management by
region, number of PICU beds
available, and type of hospital
Use of a
guideline
Use of an
asthma score
Loading dose IV
salbutamol
Increasing trend SAA
PICU admissions
Region
Northern (n = 11) 9 (82) 5 (46)* 1 (9) 6 (55)
Central (n = 13) 12 (92) 3 (25) 4 (31) 7 (54)
Southern (n = 13) 8 (62) 10 (77) 2 (15) 4 (36)
PICU beds
1–10 (n = 14) 9 (65) * 10 (77) 2 (14) 5 (39)
11–20 (n = 19) 16 (84) 6 (32) 3 (16) 9 (50)
21–30 (n = 3) 3 (100) 2 (67) 1 (33) 3 (100)
> 30 (n = 1) 1 (100) 0 (-) 1 (100) 0 (-)
Type of hospital
General (n = 1) 1 (100) 1 (100) 0 (-) 0 (-)
University (n = 20) 15 (75) 10 (50) 3 (15) 9 (47)
Children’s (n = 6) 5 (83) 2 (40) 2 (33) 3 (50)
University children’s (n = 10) 8 (80) 5 (50) 2 (20) 5 (56)
Total (n = 37) 29 (78) 18 (50) 7 (19) 17 (49)
Data presented as number (%)
*p < 0.05
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